- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2014 (2014), Article ID 792687, 6 pages
Narcolepsy as an Immune-Mediated Disease
1Stanford Center for Sleep Sciences and Medicine, Stanford University School of Medicine, 3165 Porter Drive, Palo Alto, CA 94304, USA
2Instituto de Ciencias de la Salud, Departamento de Biomedicina, Universidad Veracruzana, Industrial-Animas, 91190 Xalapa, VER, Mexico
3Laboratory of Sleep Biology, Department of Biomedicine, Institute of Health Sciences, Veracruzana University, Avenida Luis Castelazo Ayala s/n, Industrial-Animas, 91190 Xalapa, VER, Mexico
Received 30 June 2013; Revised 30 September 2013; Accepted 19 October 2013; Published 14 January 2014
Academic Editor: Michel M. Billiard
Copyright © 2014 Alberto K. De la Herrán-Arita and Fabio García-García. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- K. Sonka and M. Susta, “Diagnosis and management of central hypersomnias,” Therapeutic Advances in Neurological Disorders, vol. 5, no. 5, pp. 297–305, 2012.
- C. R. Burgess and T. E. Scammell, “Narcolepsy: neural mechanisms of sleepiness and cataplexy,” The Journal of Neuroscience, vol. 32, no. 36, pp. 12305–12311, 2012.
- E. J. Mignot, “A practical guide to the therapy of narcolepsy and hypersomnia syndromes,” Neurotherapeutics, vol. 9, no. 4, pp. 739–752, 2012.
- A. K. De la Herrán-Arita, M. Guerra-Crespo, and R. Drucker-Colín, “Narcolepsy and orexins: an example of progress in sleep research,” Frontiers in Neurology, vol. 2, article 26, 2011.
- T. Sakurai, A. Amemiya, M. Ishii et al., “Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior,” Cell, vol. 92, no. 5, pp. 573–585, 1998.
- L. de Lecea, T. S. Kilduff, C. Peyron et al., “The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 1, pp. 322–327, 1998.
- P. Bonnavion and L. de Lecea, “Hypocretins in the control of sleep and wakefulness,” Current Neurology and Neuroscience Reports, vol. 10, no. 3, pp. 174–179, 2010.
- L. Lin, J. Faraco, R. Li et al., “The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene,” Cell, vol. 98, no. 3, pp. 365–376, 1999.
- R. M. Chemelli, J. T. Willie, C. M. Sinton et al., “Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation,” Cell, vol. 98, no. 4, pp. 437–451, 1999.
- A. K. De La Herrán-Arita, V. C. Zomosa-Signoret, D. A. Millán-Aldaco et al., “Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice,” Neuroscience, vol. 183, pp. 134–143, 2011.
- S. Nishino, B. Ripley, S. Overeem, G. J. Lammers, and E. Mignot, “Hypocretin (orexin) deficiency in human narcolepsy,” The Lancet, vol. 355, no. 9197, pp. 39–40, 2000.
- E. Mignot, G. J. Lammers, B. Ripley et al., “The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias,” Archives of Neurology, vol. 59, no. 10, pp. 1553–1562, 2002.
- C. Peyron, J. Faraco, W. Rogers et al., “A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains,” Nature Medicine, vol. 6, no. 9, pp. 991–997, 2000.
- T. C. Thannickal, R. Y. Moore, R. Nienhuis et al., “Reduced number of hypocretin neurons in human narcolepsy,” Neuron, vol. 27, no. 3, pp. 469–474, 2000.
- E. Mignot, R. Hayduk, J. Black, F. C. Grumet, and C. Guilleminault, “HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients,” Sleep, vol. 20, no. 11, pp. 1012–1020, 1997.
- J. Hallmayer, J. Faraco, L. Lin, et al., “Narcolepsy is strongly associated with the T-cell receptor alpha locus,” Nature Genetics, vol. 41, no. 6, pp. 708–711, 2009.
- A. Aran, L. Lin, S. Nevsimalova et al., “Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset,” Sleep, vol. 32, no. 8, pp. 979–983, 2009.
- L. Wijnans, C. Lecomte, C. de Vries, et al., “The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns,” Vaccine, vol. 31, no. 8, pp. 1246–1254, 2013.
- H. Nohynek, J. Jokinen, M. Partinen et al., “AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland,” PLoS ONE, vol. 7, no. 3, Article ID e33536, 2012.
- M. Partinen, O. Saarenpää-Heikkilä, I. Ilveskoski et al., “Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland,” PLoS ONE, vol. 7, no. 3, Article ID e33723, 2012.
- F. Han, L. Lin, S. C. Warby et al., “Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china,” Annals of Neurology, vol. 70, no. 3, pp. 410–417, 2011.
- D. P. Singal and M. A. Blajchman, “Histocompatibility (HL A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus,” Diabetes, vol. 22, no. 6, pp. 429–432, 1973.
- A. Fontana, H. Gast, W. Reith, M. Recher, T. Birchler, and C. L. Bassetti, “Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss,” Brain, vol. 133, no. 5, pp. 1300–1311, 2010.
- V. Molina and Y. Shoenfeld, “Infection, vaccines and other environmental triggers of autoimmunity,” Autoimmunity, vol. 38, no. 3, pp. 235–245, 2005.
- P. Sfriso, A. Ghirardello, C. Botsios et al., “Infections and autoimmunity: the multifaceted relationship,” Journal of Leukocyte Biology, vol. 87, no. 3, pp. 385–395, 2010.
- J. S. Dorman and C. H. Bunker, “HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review,” Epidemiologic Reviews, vol. 22, no. 2, pp. 218–227, 2000.
- I. E. van der Horst-Bruinsma, H. Visser, J. M. W. Hazes et al., “HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis,” Human Immunology, vol. 60, no. 2, pp. 152–158, 1999.
- J. L. Newton, S. M. J. Harney, B. P. Wordsworth, and M. A. Brown, “A review of the MHC genetics of rheumatoid arthritis,” Genes and Immunity, vol. 5, no. 3, pp. 151–157, 2004.
- M. J. Simmonds, J. M. M. Howson, J. M. Heward et al., “A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect,” Human Molecular Genetics, vol. 16, no. 18, pp. 2149–2153, 2007.
- H. T. Petrie, F. Livak, D. Burtrum, and S. Mazel, “T cell receptor gene recombination patterns and mechanisms: cell death, rescue, and T cell production,” The Journal of Experimental Medicine, vol. 182, no. 1, pp. 121–127, 1995.
- A. Szakacs, N. Darin, and T. Hallböök, “Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination,” Neurology, vol. 80, pp. 1315–1321, 2013.
- E. Miller, N. Andrew, L. Stellitano et al., “Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis,” BMJ, vol. 346, article f794, 2013.
- Eurosurveillance Editorial Team, “Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy,” Euro Surveillance, vol. 16, no. 26, 2011.
- F. Han, L. Lin, J. Li, X. S. Dong, and E. Mignot, “Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic,” Annals of Neurology, vol. 73, no. 4, p. 560, 2013.
- Agence francaise de sécurité sanitaire des produits de santé, Vaccins pandémiques grippe A (H1N1) et narcolepsie—Actualisation des données—Communiqué.
- The Norwegian Medical Agency press release, Narkolepsi og Pandemrix—nye norske tall, 2011.
- Health Service Executive of Ireland, Statement re Narcolepsy/Pandemrix, 2011.